INmune Bio (INMB) continues to advance its Natural Killer cell therapy, INKmune, in a Phase I/II trial for men with metastatic castration-resistant prostate cancer, mCRPC. The Company is pleased to announce completion of the third and highest dose cohort of the Phase I portion of the trial allowing opening of the Phase II high dose cohort The Scientific Review Committee charter is to review the safety data from the patients treated in the Phase I portion of the trial as required by the FDA. Yesterday, the SRC held the third meeting evaluating the safety in INKmune therapy in men with mCRPC. The SRC unanimously voted to open all Phase II cohorts of the CaRePC trial to enrollment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- Inmune Bio’s Strategic Advancements and Promising Clinical Trials Justify Buy Rating
- INmune Bio price target raised to $23 from $22 at Scotiabank
- Inmune Bio Secures License Agreement for CORDStrom Data
- Inmune Bio Completes Phase 2 Trial for CORDStrom
- INmune Bio announces plans to submit FDA BLA for CORDStrom